Top

Published in:

01-07-2012 | Case Report

Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report

Authors: V. J. V. Vigorita, J. S. Silver, E. O. E. Eisemon

Published in: Skeletal Radiology | Issue 7/2012

Abstract

Bisphosphonates have been widely used in the treatment of an array of bone disorders. Recent complications have included unusual femoral fractures in patients who have received long term bisphosphonate treatment for osteoporosis. Although it has been shown that bisphosphonates are effective by blunting osteoclast resorption, there has been little morphologic description of the local tissue activity at the site of these unusual fractures. To evaluate for local changes to bone morphology at the fracture site in patients presenting with a bisphosphonate-related femur fracture, a sample of cortical bone was obtained at the site of a bisphosphonate fracture and was processed in a nondecalcified manner. The specimen was evaluated for potential cellular changes consistent with bisphosphonate treatment. Significant osteoclast abnormalities at the fracture site were found in a 69-year-old woman treated for 2 years with Fosamax substantiating that bone remodeling at this site is distinctly abnormal. Addressing the osteoclast dysfunction should be a focus of future therapeutic attention and intervention.

Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med. 2010;363(21):2027–35.PubMedCrossRef

Rosen CJ. Vitamin D insufficiency. N Engl J Med. 2011;364:248–53.

Bogunovic L, Kim AD, Beamer BS, Nguyen J, Lane JM. Hypovitaminosis D in patients scheduled to undergo orthopaedic surgery. A single center analysis. J Bone Joint Surg Br. 2010;92(13):2300–4.CrossRef

Stewler G. Decimal point osteoporosis at the 10 year mark. N Engl J Med. 2004;350(12):1172–4.CrossRef

Russell RG. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Med. 2007;1117:209–57.CrossRef

Scwartz Z. Osteoconductivity of demineralized bone matrix is independent of donor bisphosphonateuse. J Bone Jt Surg. 2011;93(24):2278–86.CrossRef

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society of Bone and Mineral Rresearch. J Bone Miner Res. 2010;25(11):2267–94.PubMedCrossRef

Allen MR, Ginetys E, Leeming DJ, Burr DB, Delmas PD. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporosis Intl. 2008;19(3):329–37.CrossRef

Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamge accumulation, and biochemical properties following 1 year treatment with clinical treatment doses of risedronate or alendronate. Bone. 2006;39(4):872–9.PubMedCrossRef

10.

Iwata K, Allen MR, Phipps R, Burr DB. Microcrack initiation occurs more easily in vertebrae from beagles treated with alendronate than risedronate. Bone. 2006;38(Suppl):42.CrossRef

11.

Allen MR, Reinwald S, Burr DB. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Intl. 2008;82(5):354–60.CrossRef

12.

Forwood MR, Burr DB, Takano Y, Eastman DF, Smith PN, Schwartz JD. Risedronate does not increase microdamage in the canine femoral neck. Bone. 1995;16(6):643–50.PubMedCrossRef

13.

Li J, Miller MA, Hutchins GD, Burr DB. Imaging bone microdamage in vivo with positive positron emission tomography. Bone. 2005;37(6):819–24.PubMedCrossRef

14.

Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr D. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biochemical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28(5):524–31.PubMedCrossRef

15.

Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15(4):613–20.PubMedCrossRef

16.

Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone -stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62(22):6538–44.PubMed

17.

Hughes D. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10(10):1478–87.PubMedCrossRef

18.

Coxon H. Protein geranylgeranylation is required for osteoclast formation, function and survival: inhibition by bisphosphonates and GGGTI-298. J Bone Miner Res. 2000;15(8):1467–76.PubMedCrossRef

19.

Mautalen C, Gonzales D, Blumenfeld EL, Araujo ES, Schajowicz F. Spontaneous fractures of uninvolved bones in patients with Paget’s disease during unduly prolonged with disodium etidronate (EHDP). Clin Orthop Related Res. 1986;207:150–5.

20.

Al Muderis A, Azzopardi T, Cundy P. Zebra lines of pamidronate therapy in children. J Bone Joint Surg. 2007;89:1511–6.

21.

Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med. 2006;355:2048–50.

22.

Dodson TB, Raje NS, Caruso PA, Rosenberg AE. Case 9-2008: a 65 year old woman with a non-healing ulcer of the jaw. N Engl J Med. 2008;358:1283–91.

23.

Woo S, Hande K, Richardson PG. Letter to the editor. N Engl J Med. 2005;353:100.

24.

Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009;91(11):2556–61.PubMedCrossRef

25.

De Das S, Setiobudi T, Shen L. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010;92(5):679–86.CrossRef

26.

Isaacs JD, Shidiak L, Harris IA, Szomor ZL. Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res. 2010;468:3384–92.PubMedCrossRef

27.

Lenart B, Neviaser A, Lyman S, Chang C, Edobor-Osula F, Steele B, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20(8):1353–62.PubMedCrossRef

28.

Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol. 2010;72(2):161–8.CrossRef

29.

Sayed-Noor AS, Sjoden G. Two femoral insufficiency fractures after long term alendronate therapy. Clin Orthop Relat Res. 2009;467:1921–6.PubMedCrossRef

30.

Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24(6):1095–102.PubMedCrossRef

31.

Giusti A, Hamdy NAT, Papapoulus SE. Atypical fractures of the femur and bisphosphonate therapy. A systemic review of case/case series studies. Bone. 2010;47:169–80.

32.

Black DM, Kelly M, Genant HK, Palermo L, Eastell R, Bucci-rechteg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761–71.PubMedCrossRef

33.

Somford M, Draijer F, Thomassen BJW, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long–term treatment with alendronate: clues to the mechanism of increased. J Bone Miner Res. 2009;24(10):1736–40.PubMedCrossRef

34.

Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long term oral bisphosphonate therapy. N Engl J Med. 2009 ;360:53–62.

Title: Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report
Authors: V. J. V. Vigorita
J. S. Silver
E. O. E. Eisemon
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: Skeletal Radiology / Issue 7/2012
Print ISSN: 0364-2348
Electronic ISSN: 1432-2161
DOI: https://doi.org/10.1007/s00256-012-1407-4

At a glance: The STEP trials

Springer Medicine

Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2012

Radiological findings for hip dysplasia at skeletal maturity. Validation of digital and manual measurement techniques

The value of ultrasound in assessing displacement of a medial clavicular physeal separation in an adolescent

Subpubic cyst

Indeterminate lesions on planar bone scintigraphy in lung cancer patients: SPECT, CT or SPECT-CT?

Correlation between radiological assessment of acute ankle fractures and syndesmotic injury on MRI

Double-bundle depiction of the anterior cruciate ligament at 3 Tesla